# Lanreotide In Polycystic Kidney Disease Study

> **NCT02127437** · PHASE3 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 159 (actual)

## Conditions studied

- Autosomal Dominant Polycystic Kidney Disease (ADPKD

## Interventions

- **DRUG:** Lanreotide
- **DRUG:** saline

## Key facts

- **NCT ID:** NCT02127437
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09-19
- **Primary completion:** 2019-07-31
- **Final completion:** 2019-07-31
- **Target enrollment:** 159 (ACTUAL)
- **Last updated:** 2026-04-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02127437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02127437, "Lanreotide In Polycystic Kidney Disease Study". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT02127437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*